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Abstract
Inflammation of the respiratory tract in patients with cystic fibrosis (CF) occurs at the beginning of the
disease, manifests itself even in the absence of infection. Therefore, the use of antibiotics is not
sufficient to stop the inflammation. The accumulation of sputum with high content of DNA contributes
to the development of a large amount of transforming growth factor (TGF-B). TGF-B is the mediator of
fibrosis, the rate of disease progression and pulmonary complications.
The aim is to study the role of Dornase alpha in the prevention of pulmonary fibrosis in children with
cF.
Methods: 47 children with CF were examined, among them patients without respiratory symptoms
and with chronic bronchitis. TGF-P was determined in the endothelialtissue of the bronchiand in the
blood serum.
Results: TGF-B in endothelial bronchial tissue was identified in the quarter of children. The intensity of
?iPARt;i%U F8[ RgetEp,fiiqdtSbtR?Eg i. children without chronic bronchitis. rhis is a prosnostic
ibrosis. In children with positive TGF-B
t cookies.
he blood was significantly higher. lt
was found that the treatment with Dornase alpha for 4 weeks significantly lowered TGF-B levels in
children by 12% during the exacerbation of the disease.
Conclusion: The inclusion of Dornase alpha in the treatment of patients with CF should begin even in
the absence of respiratory symptoms. Determination of serum TGF-B levels in children with CF can
help predict the severity of the course and select an optimal therapeutic strategy that will slow down
the progression of the disease.
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